Prime Therapeutics closes $1.35 billion Magellan Rx acquisition, uniting pharmacy and medical drug management expertise

The combination creates an opportunity to transform the industry by driving affordability and integrating whole-person care to enhance the patient, provider and customer experience.

December 5, 2022
Prime Therapeutics and Magellan RX Management Header

EAGAN, Minn. – Dec. 5, 2022 – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) today finalized the previously announced acquisition of Magellan Rx Management, (Magellan Rx), the pharmacy division of Magellan Health, from Centene Corporation. The agreement unites Prime’s strong foundation of pharmacy benefit management (PBM) capabilities with Magellan Rx’s industry-leading total specialty drug management expertise to create a diversified pharmacy solutions organization serving commercial markets and government programs.

“This is a rare opportunity to bring together two highly respected organizations to create an enterprise that is greater than the sum of its parts. Together, we will deliver on the health care Quadruple Aim – affordability, patient service, improved health and engagement with caregivers,” said Ken Paulus, president and CEO of Prime Therapeutics.

The agreement includes the following Magellan Rx business segments:

  • Specialty drug management, providing leading-edge solutions across both the pharmacy and medical benefit, clinical programs and formulary management services; and full-service specialty pharmacies.
  • A market-leading state government division, serving 28 states and the District of Columbia.
  • A full-service PBM, serving 1.7 million members.

For the time being, Magellan Rx will operate independently to focus on existing customer commitments, and, in the coming months, we will work to integrate select business units and functions and begin to assess our strategic alignment and further integration. Mostafa Kamal will continue as Magellan Rx CEO and will join Prime’s executive leadership team. The combined enterprise will have a single go-to-market structure built around three distinct lines of business — PBM services, specialty drug management and state government solutions. Prime will also continue to provide select services to smaller PBMs.

“We’re bringing some of the brightest minds and most dedicated teams in pharmacy together to develop and deliver a next-generation care model that will transform the industry, unlock new possibilities and deliver even more value to those we serve,” said Mostafa Kamal, CEO of Magellan Rx.

Integration planning for the two companies is underway. Both brands will remain in the market for up to a year as the company explores new brand opportunities that convey the innovation, energy and power the combined enterprise brings to the market.

Prime and Magellan Rx are creating a vibrant new market alternative

Related news

Press releases

July 10, 2024

Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years 

Real-world, integrated data follows-up on previous insights, analytics

Press releases

July 8, 2024

Prime Therapeutics hires new CIO to lead digital transformation 

Dinesh Kandanchatha joined the organization July 1

Press releases

June 19, 2024

Prime/MRx’s new Pharmacy Match technology-driven solution expands specialty pharmacy access and choice

Using real-time pricing, Pharmacy Match drives affordability for plan sponsors while offering access to the most competitive pharmacy for each member